Search Results
18 protocol(s) meet the specified criteria
Phase I, Open-Label, Multicenter, Dose-Escalation Study of mRNA-2416, a Lipid Nanoparticle Encapsulated mRNA Encoding Human Ox40l, for Intratumoral Injection to Patients with Advanced Malignancies

Phase I/IB, Open-Label, Multicenter, Dose-Escalation Study of NIS793 in Combination with PDR001 in Adult Patients with Advanced Malignancies

Observational Study Assessing the Clinical Effectiveness of VeriStrat® and Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Phase I/II, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors

Multi-Tracer PET Assessment of Response in Various Malignancies in Investigational and Recently Approved Therapeutic Agents

Phase I/IB Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

Phase I/IIA Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

Phase I/II, Open-Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination with PDR001 Administered to Patients with Advanced Malignancies

Pivotal Multicenter, Randomized, Controlled, Single-Blinded Study Comparing the Silver Nitrate-Coated Indwelling Pleural Catheter (SNCIPC) to the Uncoated PleurX® Pleural Catheter for the Management of Symptomatic, Recurrent, Malignant Pleural Effusions

Phase II, Multicenter, Four-Cohort Study of Oral cMET Inhibitor INC280 in Adult Patients with EGFR Wild-Type (WT), Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Received One or Two Prior Lines of Systemic Therapy for Advanced/Metastatic Disease

Phase I, Dose-Finding, and Signal-Seeking Study of the Safety and Efficacy of Intravenous Cavataktm Alone and in Combination with Pembrolizumab in Patients with Late Stage Solid Tumours (NSCLC and Bladder Cancer)

Phase IB, Open-Label, Multicenter Study to Characterize the Safety, Tolerability, and Pharmacodynamics (PD) of PDR001 in Combination with LCL161, Everolimus (RAD001), or Panobinostat (LBH589)

Phase II, Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)

Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) versus Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy

Phase II Trial of Trametinib with Docetaxel in Patients with KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies

Open-Label Phase I/II Study of INCB039110 in Combination with Osimertinib in Subjects with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Randomized, Open-Label, Phase III Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC

Phase I Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors